Literature DB >> 7805231

Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction.

C L Grines1, E J Topol, W W O'Neill, B S George, D Kereiakes, H R Phillips, J D Leimberger, L H Woodlief, R M Califf.   

Abstract

BACKGROUND: Smoking is known to be a strong risk factor for premature atherosclerosis, myocardial infarction, and sudden cardiac death. Unexpectedly, in the reperfusion era, investigators have reported that patients who smoke have a more favorable prognosis after thrombolysis compared with non-smokers. Since smoking is associated with a relatively hyper-coagulable state, we hypothesized that the coronary occlusion responsible for infarction may be primarily thrombotic, with improved outcome relating to enhanced patency or the absence of a residual stenosis after thrombolytic therapy. METHODS AND
RESULTS: To examine this issue, we evaluated 1619 patients treated with TPA, urokinase, or both in six consecutive myocardial infarction trials, of whom 878 (54%) were currently smoking. Patients underwent 90-minute and predischarge catheterizations, which were quantified blinded to the patients' smoking status. As expected, baseline fibrinogen (2.8 [2.5,3.6] versus 2.7 [2.4,3.5] g/dL, P = .003) and hematocrit (44% [41%, 47%] versus 43% [40%, 45%], P = .0001) levels were greater in smokers. Although there were no differences between smokers and nonsmokers with regard to 90-minute patency (73% versus 74%), smokers were more likely to have TIMI-3 flow (41.1% versus 34.6%, P = .034), with a larger minimum lumen diameter of the infarct stenosis both acutely (0.82 [0.51, 1.11] versus 0.72 [0.43, 1.04] mm, P = .0432) and at follow-up (1.2 [0.8, 1.74] versus 1.0 [0.7, 1.5], P = .002). Although smokers tended to have reduced in-hospital mortality compared with nonsmokers in univariate analysis (4.0% versus 8.9%, P = .0001), after adjustment for baseline differences between smokers and nonsmokers in age (54 [47, 62] versus 60 [54, 68] years, P < .0001), inferior infarct location (60% versus 53%, P < .0001), three-vessel disease (16% versus 22%, P < .001), and baseline ejection fraction (53% [44%, 60%] versus 50% [42%, 58%], P = .0069), smoking history was of no independent prognostic significance.
CONCLUSIONS: Therefore, smokers have a relatively hypercoagulable state, documented by increased hematocrit and fibrinogen levels. Quantitative coronary angiographic analysis suggests that the mechanism of infarction in smokers is more often thrombosis of a less critical atherosclerotic lesion compared with nonsmokers. Enhanced perfusion status, as well as favorable baseline clinical and angiographic characteristics, may be responsible for the more benign prognosis of current smokers.

Entities:  

Mesh:

Year:  1995        PMID: 7805231     DOI: 10.1161/01.cir.91.2.298

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  32 in total

1.  Cumulative burden of atherosclerotic risk genotypes and the age at onset of a first myocardial infarction: a case-only carriership approach.

Authors:  Ilan Goldenberg; Arthur J Moss; Daniel Ryan; Grzegorz Pietrasik; Wojciech Zareba; Scott McNitt; Shirley W Eberly
Journal:  Ann Noninvasive Electrocardiol       Date:  2008-07       Impact factor: 1.468

2.  Coronary artery bypass surgery in smokers.

Authors:  E Shelley
Journal:  Heart       Date:  1996-06       Impact factor: 5.994

3.  Impact of smoking status on cardiovascular outcomes following percutaneous coronary intervention.

Authors:  Burhan Mohamedali; Adhir Shroff
Journal:  Clin Cardiol       Date:  2013-05-13       Impact factor: 2.882

4.  Smoking cessation program with exercise improves cardiovascular disease biomarkers in sedentary women.

Authors:  Tellervo Korhonen; Amy Goodwin; Petra Miesmaa; Elizabeth A Dupuis; Taru Kinnunen
Journal:  J Womens Health (Larchmt)       Date:  2011-06-15       Impact factor: 2.681

5.  Cardiovascular risk factors and clinical presentation in acute coronary syndromes.

Authors:  A Rosengren; L Wallentin; M Simoons; A K Gitt; S Behar; A Battler; D Hasdai
Journal:  Heart       Date:  2005-09       Impact factor: 5.994

6.  Smoking out the cause of thrombosis.

Authors:  Robert A Campbell; Kellie R Machlus; Alisa S Wolberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-01       Impact factor: 8.311

7.  Smoking, clopidogrel, and mortality in patients with established cardiovascular disease.

Authors:  Jeffrey S Berger; Deepak L Bhatt; Steven R Steinhubl; Mingyuan Shao; P Gabriel Steg; Gilles Montalescot; Werner Hacke; Keith A Fox; A Michael Lincoff; Eric J Topol; Peter B Berger
Journal:  Circulation       Date:  2009-11-23       Impact factor: 29.690

8.  The smoker's paradox after successful fibrinolysis: reduced risk of reocclusion but no improved long-term cardiac outcome.

Authors:  Peter C Kievit; Marc A Brouwer; Gerrit Veen; Wim R M Aengevaeren; Freek W A Verheugt
Journal:  J Thromb Thrombolysis       Date:  2008-06-26       Impact factor: 2.300

9.  Is preconditioning by nicotine responsible for the better prognosis in smokers with acute myocardial infarction?

Authors:  Y Birnbaum; S L Hale; R A Kloner
Journal:  Basic Res Cardiol       Date:  1996 May-Jun       Impact factor: 17.165

10.  The smoker's paradox: insights from the angiographic substudies of the TIMI trials.

Authors:  Brad G Angeja; Sarah Kermgard; Michael S Chen; Matthew McKay; Sabina A Murphy; Elliott M Antman; Christopher P Cannon; Eugene Braunwald; C Michael Gibson
Journal:  J Thromb Thrombolysis       Date:  2002-06       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.